Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension
This pioneering study investigated the real-life effectiveness of single-pill combination (SPC) antihypertensive therapy in patients with uncontrolled blood pressure (BP) and cardiovascular risk factors. After treatment with olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide for 24 weeks, adults with apparent resistant hypertension had significantly reduced systolic BP and approximately 80% achieved target BP. SPC therapy may improve adherence in patients with pseudo-resistant hypertension and is a potentially effective treatment for resistant hypertension.
Authors
- Hack‐Lyoung Kim (ORCID: https://orcid.org/0000-0002-6703-1472)
- Jaewon Oh (ORCID: https://orcid.org/0000-0002-4585-1488)
- Soo Kyung Lim (ORCID: https://orcid.org/0000-0002-4137-1671)
- Gee-Hee Kim (ORCID: https://orcid.org/0000-0002-0279-7370)
- Ji-Hwan Bae (ORCID: https://orcid.org/0000-0002-5383-9761)
- Jun Hwa Hong (ORCID: https://orcid.org/0000-0002-8693-1038)
- Jinho Shin (ORCID: https://orcid.org/0000-0001-6706-6504)
- Wonho Kim (ORCID: https://orcid.org/0000-0001-7036-449X)
- Kyung Wan Min
- Dong Keun Hyun (ORCID: https://orcid.org/0000-0002-9318-5985)
- Sang‐Don Park (ORCID: https://orcid.org/0000-0003-0128-9988)
Institutions
- Seoul National University (KR)
- Inha University (KR)
- Yonsei University (KR)
- Eulji University (KR)
- Seoul National University Bundang Hospital (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- SNUH SMG-SNU Boramae Medical Center (KR)
- Daejeon Eulji Medical Center, Eulji University (KR)
- Daiichi-Sankyo (South Korea) (KR)
- Gangnam Severance Hospital (KR)
- Inha University Hospital (KR)
- Hanyang University (KR)
Publication Details
- Journal
- Journal of Human Hypertension
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1038/s41371-025-01043-3
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Daiichi Sankyo Europe